Toronto, October 02, 2025 (Globe Newswire) -ALGAE-C InC. (“Algae-C”) today is issuing a correction in the previous release announcing its acquisition of Rockcliffe Labs Inc. (“Rockcliffe Labs”). The previous release suggested that all the algae cubicated and outstanding securities were exchanged for Rockcliffe Labs shares.
This correction explains that RockCliffe Labs has acquired a control share in algae C for consideration of funds. Financial conditions are unsolved. Algae-C is now working as a subsidiary owned by the majority of Labs. The remaining algae-C shareholders continue exclusively as the Algae-C minoritarian shareholders and do not have any capital, economic or voting in Rockcliffe Labs.
All other details from the previous announcements remain unchanged.
Algae-C Inc. announces the completion of the acquisition of Rockcliffe Labs Inc.
Algae-C Inc. (Algae-C) today announced that Rockcliffe Labs Inc. (Rockcliffe Labs) acquired a control share in algae C for consideration of funds. Financial conditions are unsolved. Algae-C is now working as a subsidiary owned by the majority of Labs. The remaining algae-C shareholders continue exclusively as the Algae-C minoritarian shareholders and do not have any capital, economic or voting in Rockcliffe Labs.
Review of the transaction
- Management: operations and management of AlgaE-C will be integrated into the RockCliffe Labs management and reporting frame.
- Structure: RockCliffe Labs has gained control of algae C due to the purchase of most securities.
- Consideration: Acquisition was settled in cash, with financial conditions of unsolved
- Property right: Rockcliffe Labs now holds a control joint stock position, while outdated shareholders retain the interests of the minority.
Strategic justification
The acquisition promotes the Rockcliffe Labs strategy to create a diversified biotechnological platform by adding molecular and production technologies and the production of algae. The united essence expects to obtain extraction from:
- Expansion of the pipeline: AlgaE-C library with more than 600 identified molecules, including compounds with pharmaceutical, nutrifental, cosmetic and industrial use.
- Platform synergism: Integration of the portfolio of IP addresses and technical experts of the IP Algae-C with clinical, regulatory and commercialization infrastructure RockCliffe Labs.
- Commercial ways: advanced opportunities for licensing, joint development and supplies supported by scalable biopriet processes.
- Portfolio diversification: risk dispersion in several therapeutic and non-technology programs as part of the Multi-SSET development model in Rockcliffe Labs.
Integration plan
Rockcliffe Labs intends to:
- Maintain existing Algae-C research operations as a specialized unit on a wider platform.
- The preliminary priority of algae obtained from algae into validation and preclinical development.
- Joint intellectual property, quality and regulatory practices with central Rockcliffe Labs systems.
- Conducting strategic partnerships and licensing agreements to accelerate commercialization.
Capitalization
After completing the acquisition, former AlgaE-C shareholders together are faced with property in Rockcliffe Labs, along with existing Rockcliffe Labs shareholders and strategic partners, including the Canadian University, which occupies a minority in accordance with the licensing agreement.
About hydrogen-C
Algae-C Inc. It is a Canadian biotechnological company dedicated to molecular discoveries and algae -based production. Its patented technology provides scalable, stable production of high connections using healthcare, health and advanced materials.
About Rockcliff -laboratory
Rockcliffe Labs Inc. – This is the Canadian platform of the creation of biotechnological enterprises, which integrates academic discoveries with clinical, regulating and capital experience. Thanks to licensing and acquisitions, Rockcliffe Labs creates diversified diversified diversified pipelines covering pharmaceuticals, diagnosis and biological technologies.
Advanced information
This press release contains “informative information” in the meaning of applicable Canadian laws on securities, including statements about the expected advantages of acquiring, integration of algae in the Rockcliff laboratory, expected synergy, future development and commercialization. Advanced information is based on current expectations and assumptions and is subject to risks and uncertainty, including scientific, regulatory, financial and competitive risks that can lead to significantly different results. With the exception of cases required by law, neither algae nor the RockCliff laboratories are doing any obligations to update or revise information.
There is no offer or appeal
This press release is not a proposal for the sale or proposal for the purchase of any securities in any jurisdiction. Any securities issued in connection with the acquisition were distributed depending on the release of the avenue available in accordance with applicable Canadian laws on securities.
Media and investor contacts
Algae-C Inc. (Media)
E-mail: [email protected]
Algae-C Inc. (investors)
E-mail: [email protected]
